- Home
- RVTY vs JAZZ Comparison
RVTY vs JAZZ Comparison
Compare RVTY & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVTY | JAZZ |
|---|---|---|
| Founded | 1937 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.4B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | RVTY | JAZZ |
|---|---|---|
| Price | $95.74 | $165.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $113.00 | ★ $207.19 |
| AVG Volume (30 Days) | ★ 1.6M | 774.0K |
| Earning Date | 02-02-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | $2,856,051,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $6.06 | $6.19 |
| Revenue Next Year | $5.15 | $6.46 |
| P/E Ratio | $46.68 | ★ N/A |
| Revenue Growth | 3.67 | ★ 4.14 |
| 52 Week Low | $81.36 | $95.49 |
| 52 Week High | $120.39 | $182.99 |
Technical Indicators
Market Signals| Indicator | RVTY | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 53.03 |
| Support Level | $93.70 | $161.38 |
| Resistance Level | $106.55 | $167.73 |
| Average True Range (ATR) | 4.33 | 3.88 |
| MACD | -1.62 | 0.07 |
| Stochastic Oscillator | 15.05 | 74.32 |
Price Performance
Historical ComparisonAbout RVTY Revvity Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.